Generation of CD20-specific TCRs for TCR gene therapy of CD20(low) B-cell malignancies insusceptible to CD20-targeting antibodies

Immunotherapy of B-cell leukemia and lymphoma with CD20-targeting monoclonal antibodies (mAbs) has demonstrated clinical efficacy. However, the emergence of unresponsive disease due to low or absent cell surface CD20 urges the need to develop additional strategies. In contrast to mAbs, T-cells via t...

Descripción completa

Detalles Bibliográficos
Autores principales: Jahn, Lorenz, van der Steen, Dirk M., Hagedoorn, Renate S., Hombrink, Pleun, Kester, Michel G.D., Schoonakker, Marjolein P., de Ridder, Daniëlle, van Veelen, Peter A., Falkenburg, J.H. Frederik, Heemskerk, Mirjam H.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363567/
https://www.ncbi.nlm.nih.gov/pubmed/27776339
http://dx.doi.org/10.18632/oncotarget.12778

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363567/
https://www.ncbi.nlm.nih.gov/pubmed/27776339
http://dx.doi.org/10.18632/oncotarget.12778

Ejemplares similares